4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-022704
CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $22.49 ($269,841)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-08-29 | Sale : show line 1 in the form 10b5-1 | −11,950 | $22.48 | $268,687 | 1,077,986 | I |
| 2024-08-29 | Sale : show line 2 in the form 10b5-1 | −50 | $23.08 | $1,154 | 1,077,936 | I |
| Open-market sales · 12,000 sh · avg $22.49 · $269,841 | ||||||
Loading xslF345X05/form4-09032024_090954.xml…